Ubs Group Ag Bio Line Rx Ltd. Put Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding BLRX
# of Institutions
39Shares Held
3.34MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$121,3090.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$114,1954.05% of portfolio
-
Envestnet Asset Management Inc239KShares$33,4860.0% of portfolio
-
Morgan Stanley New York, NY198KShares$27,6550.0% of portfolio
-
Values First Advisors, Inc.198KShares$27,6520.06% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $8.61M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...